Impact of adding maraviroc to antiretroviral regimens in patients with full viral suppression but impaired CD4 recovery.
We reviewed the effect of adding maraviroc on CD4 cell counts in nine patients on antiretroviral therapy with full viral suppression but impaired CD4 cell recovery. There were no significant differences in changes in CD4 cell count, percentage of CD4 cells, or in the ratio of CD4/CD8 cells at 30 days and 25 weeks of maraviroc therapy. Plasma endotoxin levels measured in four patients before and during maraviroc treatment also showed no significant differences.
Stepanyuk
Olena
O
Infectious Diseases Section, Veterans Affairs New Jersey Health Care System, East Orange, NJ, USA.
Chiang
Tom S
TS
Dever
Lisa L
LL
Paez
Sandra L
SL
Smith
Sharon M
SM
Perez
George
G
Eng
Robert H K
RH
D000368:Aged; D023241:Antiretroviral Therapy, Highly Active / Q000379:methods; D018791:CD4 Lymphocyte Count; D003510:Cyclohexanes / Q000627:therapeutic use*; D004341:Drug Evaluation; D004731:Endotoxins / Q000097:blood; D023581:HIV Fusion Inhibitors / Q000627:therapeutic use*; D015658:HIV Infections / Q000188:drug therapy* / Q000276:immunology / Q000821:virology; D015497:HIV-1 / Q000302:isolation & purification*; D006801:Humans; D008297:Male; D000077592:Maraviroc; D008875:Middle Aged; D012367:RNA, Viral / Q000097:blood; D012189:Retrospective Studies; D016896:Treatment Outcome; D014230:Triazoles / Q000627:therapeutic use*
D003510:Cyclohexanes; D004731:Endotoxins; D023581:HIV Fusion Inhibitors; D012367:RNA, Viral; D014230:Triazoles; D000077592:Maraviroc